Phospholipase C epsilon (PLCε) has been characterized as a direct effector of Ras in vitro and in cellular systems; however, the role of PLCε in tumorigenesis and its link to Ras in this context remain unclear. To assess the role of PLCε in Ras driven cancers, we generated two new mouse strains: one carrying a targeted deletion of Plce (Plce 
was confirmed by RT-PCR of various organs using primers for exon 2-3 (Fig. 1D, top) . Point mutations generated in exon 29 and 30 of Plce RAm/RAm were verified in different organs based on the presence of specific restriction sites (Fig. 1D, bottom) . In addition, the absence of and Plce -/-MEFs were used for Western blotting and showed no significant difference of expression of other PLCs (Supplemental Fig. S1C ).
Two-stage chemical skin carcinogenesis
Before As shown in Fig. 2B , our results clearly show that the loss of PLCε leads to a significant increase in tumour burden compared to the wild type control mice. Similarly,
Plce
RAm/RAm mice also exhibited increase in tumour burden when compared to the wild type, suggesting that absence of signalling mediated by the RA2 domain of PLCε increases susceptibility to tumour development; however, mice with a total absence of PLCε exhibited an aggravated phenotype (Fig. 2B ). We also excluded the possibility that the enhancement in tumour development was due to a reduction in apoptosis (Supplemental Fig. S3C ).
When tumour volume was assessed at 13 weeks of treatment, Plce -/-mice had significantly bigger tumours than those seen in the wild type while no significant difference was seen between Plce +/+ and Plce RAm/RAm (Fig. 2C ). This suggests that RA2 domain could contribute to suppression of tumour formation without significantly affecting tumour growth.
In contrast, complete ablation of PLCε has an effect on both processes, affecting number and size of tumours.
Unexpectedly, the survival rate of the Plce -/-mice was drastically affected during the treatment ( Although to our knowledge, FVB vs C57BL/6 outcrossing to identify susceptibility genes has not been done, our data suggest that in the F1 (FVBxC57BL/6) generation a C57BL/6
derived "tumor survival" allele is present which could be associated with PLCε tumour suppressor or other roles relevant for tumour formation.
We also examined epidermal hyperplasia in TPA-treated skin in order to determine the potential effect of PLCε in the second proliferative step of the two chemical carcinogenesis protocol. Initial measurements of the skin thickness on day 2 showed that a single topical application of TPA at 10 µg induced thickening of the epidermis in all Figure 3C ) were seen for the Plce RAm/RAm allele when using TSA and AZA (Supplemental Fig. S5A ). Varying growth conditions and prolonged stimulations of MEFs did not affect expression levels of PLCε (Supplemental Fig. S5B and C).
To further analyse expression levels of PLCε during DMBA-TPA treatment we crossed our C57Bl/6J mice with a background known to be more resistant to the DMBA-TPA treatment, the DBA mice, enabling us to slow down the tumourigenesis process and study treated skin that did not develop tumours. Wild type F1 mice (C57Bl/6J-DBA) were treated as previously and non-treated skin, treated skin and tumours were analysed at week 13 of the DMBA-TPA treatment. The three mice analysed showed an 80% downregulation of PLCε in treated skin (in the absence of lesions) compared to untreated (ventral) skin (Fig 3.D) . This suggests that the down-regulation of PLCε also occur prior to tumour formation and is probably mediated by the TPA-promotion step. Overall, these results propose that activated mutations in the Hras gene can directly downregulate PLCε in cells, however, continuous skin treatment with TPA also down-regulates PLCε prior to tumour formation.
Our further experiments also suggested that exogenous expression of the wild-type
PLCε in Plce -/-MEFs resulted in a reduction in cell proliferation; this effect seems to be dependent on intact lipase activity (Supplemental Fig. S6A ). Consistent with this, reexpression of PLCε corresponded to an increase in PKC activity (as assessed by phosphorylation of PKC and its substrate MARCKS) (Supplemental Fig. S6B and C). As shown in Fig. S6D , we observed similar changes in pre-cancer skin from Plce -/-mice that is characterized by higher rate of proliferation (Fig. 2E ). This suggests that the predominant mechanism that impacts on cell proliferation is mediated by PKC; isozymes previously linked to growth inhibition such as PKCδ or PKCη (30), are likely to be involved.
Kras driven lung tumour development
To further investigate the tumour suppressor function of PLCε, we used the conditional LSL-Kras G12D NSCLC model. PLCε expression is highest in the lung ( Malignancy was assessed by counting the number of solid nodules and fraction of animals having solid tumours per genotype, which also did not show any significant difference between the genotypes ( Fig. 4D and E).
PLCε expression (assessed by qPCR) was analysed in the whole, wild type untreated lungs and lungs from mice 26 weeks after AdCre infection showing 38% reduction (Fig. 4F) .
In vitro analysis of LSL-Kras G12D MEFs showed a rapid down-regulation of PLCε after AdCre infection; 50% of PLCε reduction 6 days after AdCre infection (Fig. 4G) 
PLCε downregulation in human lung tumours and cell lines
To investigate whether PLCε would also be down-regulated in human lung tumours, Taken together with previously published observations, our comprehensive study, including animal models, suggests that PLCε has tumour suppressive functions in the formation of several cancer types (including CRC, lung and skin), and that its marked downregulation could be a useful biological marker in their assessment and treatment. 
Materials and Methods

Generation of Plce
B. Strategies for generation of Plce1 null (left) and Plce
RAm/RAm (right) alleles. Volume of the three largest tumours per animal was measured at week 13 after DMBA treatment.
C. Number and percentage (%) of offsprings generated from
The above procedure was also carried out using C57BL/6J wild-type animal crossed with DBA and three F1 C57BL/6J-DBA mice were treated as outlined. 13
weeks after DMBA treatment animals were sacrificed and treated (dorsal area), nontreated skin (ventral area) and two separate tumours were removed from each animal for analysis. In situ hybridization. In situ hybridization was carried out as previously described (5). To detect Plce transcripts two digoxigenin-labelled RNA probes were generated using in vitro RNA labelling Kit (Roche). Both probes, hybridizing respectively exon 1 to 3 and 6 to 8 of the wild-type PLCε RNA gave similar specificity.
12-O-tetradecanoyl-phorbor-13-acetate induced skin hyperplasia.
Cell culture. MEFs were isolated from C57Bl/6J mouse embryos at 13.5 days of gestation as described in (1) . Primary MEFs were immortalized by infection with retrovirus pBABE-Hygro p53DD (Addgene) and selected in Hygromycin B (Sigma) (200µg/ml) for over one week. Retrovirus infection of pBABE-Puro HrasV12 was performed on primary or immortalized p53DD MEFs and cells were selected at 2.5μg/ml of Puromycin (Sigma) for four days.
Primary LSL-Kras G12D MEFs were transfected with AdCreGFP and AdGFP and total RNA was extracted 2, 4 and 6 days after adenovirus infection. were serum starved for 15 hrs and stimulated by 400 nM LPA (in a medium containing 5%FBS) for 2 minutes (left panels). Following this verification of reagents and methodology in a short stimulation, the control transformed MEFs (vector) and
MEFs expressing PLCε (PLCε WT) were analysed when grown under conditions described in A, after 3 days of seeding (right panels).
Cell lysates (150 µg) were analysed by Western blotting using indicated antibodies with α-actinin as a loading control. For the analyses of GTP-bound state of Rap1, lysates were first incubated with GST-fusion RalGDS-RBD and the protein present in the "pull-down" subsequently analysed by Western blotting using antibodies to Rap1.
The differences between the control MEFs (vector) and MEFs expressing PLCε 
